how big is Jubilant Pharmo?

As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, with recent net sales of 7,234.50 Cr and a net profit of 839.40 Cr for the latest four quarters.

Market Cap: As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 7,234.50 Cr and a sum of Net Profit of 839.40 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 5,433.90 Cr, and the Total Assets amount to 11,315.80 Cr.

When is the next results date for Jubilant Pharmo?

No Upcoming Board Meetings

Who are in the management team of Jubilant Pharmo?

As of March 2023, the management team of Jubilant Pharmo includes Shyam S Bhartia (Chairman), Hari S Bhartia (Co-Chairman), Priyavrat Bhartia (Managing Director), and Arjun Shanker Bhartia (Joint Managing Director), along with several non-executive and independent directors. This diverse team oversees the company's governance and strategic direction.

As of March 2023, the management team of Jubilant Pharmo includes the following individuals:<BR><BR>1. Shyam S Bhartia - Chairman (Non-Executive)<BR>2. Hari S Bhartia - Co-Chairman & Non-Executive Director<BR>3. S Sridhar - Non-Executive & Independent Director<BR>4. Sudha Pillai - Non-Executive & Independent Director<BR>5. Ashok Misra - Non-Executive & Independent Director<BR>6. Vivek Mehra - Non-Executive & Independent Director<BR>7. Sushil Kumar Roongta - Non-Executive & Independent Director<BR>8. Priyavrat Bhartia - Managing Director<BR>9. Arjun Shanker Bhartia - Joint Managing Director<BR>10. Arun Seth - Non-Executive & Independent Director<BR>11. Arvind Chokhany - Whole Time Director & CFO<BR>12. Naresh Kapoor - Company Secretary & Compliance Officer<BR>13. R Kumar - Whole Time Director<BR>14. Shirish Gundopant Belapure - Independent Director<BR><BR>This diverse team includes both executive and non-executive members, contributing to the governance and strategic direction of the company.

What does Jubilant Pharmo do?

Jubilant Pharmova Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹1,929 Cr and a net profit of ₹154 Cr for March 2025. The company, formerly known as Jubilant Life Sciences, has a market cap of ₹18,236 Cr and key metrics including a P/E ratio of 38.00 and a dividend yield of 0.44%.

Overview:<BR>Jubilant Pharmova Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Vam Organic Chemicals Limited' in 1978. It underwent several name changes, becoming 'Jubilant Organosys Limited' in November 2001, 'Jubilant Life Sciences Limited' in October 2009, and finally 'Jubilant Pharmova Limited' in February 2021. The most recent quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,929 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 154 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 18,236 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.44%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 7.75%<BR>- Price to Book: 2.92<BR><BR>Contact Details:<BR>- Address: Bhartiagram Gajraula, Amroha Uttar Pradesh: 244223<BR>- Phone: 91-5924-267200<BR>- Email: investors@jubl.com/support@jubl.com<BR>- Website: http://www.jubilantpharmova.com

Has Jubilant Pharmo declared dividend?

Yes, Jubilant Pharmova Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over longer periods, despite some short-term fluctuations.

Jubilant Pharmova Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 02 Aug 2024<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -5.83%, the dividend return was 0%, resulting in a total return of -5.83%.<BR><BR>For the 1 year period, the price return was 58.16%, the dividend return was 0.68%, leading to a total return of 58.84%.<BR><BR>Over the 2 years period, the price return was 235.09%, the dividend return was 2.44%, culminating in a total return of 237.53%.<BR><BR>In the 3 years period, the price return was 185.02%, the dividend return was 4.65%, which resulted in a total return of 189.67%.<BR><BR>During the 4 years period, the price return was 36.31%, the dividend return was 2.71%, giving a total return of 39.02%.<BR><BR>For the 5 years period, the price return was 98.97%, the dividend return was 2.94%, resulting in a total return of 101.91%.<BR><BR>Overall, Jubilant Pharmova Ltd has declared a significant dividend, and the total returns over various periods show a positive trend, particularly in the longer terms, indicating strong performance despite some short-term fluctuations.

Who are the peers of the Jubilant Pharmo?

Jubilant Pharmo's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life. In terms of management risk, growth, and capital structure, Jubilant Pharmo is rated average, while its 1-year return of 68.61% is higher than Natco Pharma's but lower than Blue Jet Health's 139.69%.

Peers: The peers of Jubilant Pharmo are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life, and Average management risk is noted for Jubilant Pharmo. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have Below Average or Good growth ratings, with Divi's Lab. showing Below Average growth, and Concord Biotech showing Good growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Concord Biotech, and Caplin Point Lab, while Good is noted for Torrent Pharma, and Average for Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 139.69%, while Natco Pharma has the lowest at -13.50%. Jubilant Pharmo's 1-year return of 68.61% is significantly higher than Natco Pharma's but lower than Blue Jet Health's. Additionally, Natco Pharma and Concord Biotech have negative six-month returns.

Who are the top shareholders of the Jubilant Pharmo?

The top shareholders of Jubilant Pharma include Spb Trustee Company Pvt Ltd with 20.52%, 18 mutual fund schemes holding 3.66%, 151 foreign institutional investors at 17.22%, and East Bridge Capital Master Fund I Ltd as the largest public shareholder with 4.3%. Individual investors collectively own 17.75% of the shares.

The top shareholders of Jubilant Pharma include a mix of promoters and institutional investors. The majority shareholders are the promoters, with Spb Trustee Company Pvt Ltd holding the largest stake at 20.52%. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively hold 3.66% of the company, while 151 foreign institutional investors (FIIs) account for 17.22%. The highest public shareholder is East Bridge Capital Master Fund I Ltd, which holds 4.3%. Additionally, individual investors collectively own 17.75% of the shares.

Are Jubilant Pharmo latest results good or bad?

Jubilant Pharmova's Q2 FY26 results are generally positive, with a 17.02% increase in net profit and a 12.22% rise in revenue, marking the highest quarterly revenue in the company's history. However, concerns about low return on equity and underperformance compared to the market suggest caution regarding long-term growth prospects.

Jubilant Pharmova's latest results for Q2 FY26 can be characterized as generally positive, showcasing improvements in key financial metrics. The company reported a net profit of ₹120.30 crores, which reflects a 17.02% increase year-on-year. Revenue also saw a healthy growth of 12.22% compared to the previous year, with net sales reaching ₹1,966.40 crores, marking the highest quarterly revenue in the company's recent history.<BR><BR>Additionally, the operating margin improved to 17.44%, up from 16.61% in the same quarter last year, indicating better operational efficiency and cost management. The sequential growth in net profit of 16.91% from the previous quarter further underscores this positive trend.<BR><BR>However, despite these encouraging results, there are some concerns. The return on equity (ROE) remains relatively low at 7.75%, which is below industry standards, raising questions about the company's long-term capital efficiency and profitability. Furthermore, the stock has underperformed the broader market over the past year, declining 10.20% compared to the Sensex's 5.73% gain.<BR><BR>In summary, while Jubilant Pharmova's recent results show strong revenue and profit growth, the underlying issues related to return ratios and stock performance may temper investor sentiment. Overall, the results can be seen as good in the context of operational improvements, but caution is warranted regarding long-term growth prospects.

Is Jubilant Pharmo overvalued or undervalued?

As of November 3, 2025, Jubilant Pharma is fairly valued with a PE ratio of 37.37 and an EV to EBITDA of 14.49, positioned between peers like Sun Pharma and Cipla, despite facing challenges with an -8.16% return over the past year.

As of 3 November 2025, the valuation grade for Jubilant Pharmo has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 37.37, an EV to EBITDA of 14.49, and a PEG ratio of 1.35. In comparison to its peers, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, indicating that Jubilant Pharmo is positioned in the middle range of its industry.<BR><BR>Despite recent stock performance showing a 4.09% gain over the past week compared to a -0.94% decline in the Sensex, the company's longer-term returns, particularly a -8.16% return over the past year, suggest some challenges ahead. Overall, the current valuation reflects a balance between growth expectations and market realities, placing Jubilant Pharmo in a fair valuation category amidst its peers.

How has been the historical performance of Jubilant Pharmo?

Jubilant Pharmo's historical performance shows fluctuating financial metrics, with net sales increasing from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025, despite a peak of INR 9,110.82 crore in March 2019. The company has rebounded in profitability, with profit after tax rising to INR 836.80 crore in March 2025 from a loss of INR 77.13 crore in March 2023.

Answer:<BR>The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Pharmo's net sales have shown a steady increase from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025. However, this is a decline from the peak of INR 9,110.82 crore in March 2019. The total operating income followed a similar trend, reaching INR 7,234.50 crore in March 2025. The total expenditure, excluding depreciation, increased from INR 4,973.83 crore in March 2022 to INR 6,060.80 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 1,739.01 crore in March 2019 and dropping to INR 1,230.50 crore in March 2025. Profit before tax saw a significant recovery to INR 981.10 crore in March 2025, up from just INR 15.53 crore in March 2023. Profit after tax also rebounded to INR 836.80 crore in March 2025, compared to a loss of INR 77.13 crore in March 2023. The company's total assets increased from INR 9,829.60 crore in March 2022 to INR 12,499.00 crore in March 2025, while total liabilities rose from INR 9,829.60 crore to INR 12,499.00 crore in the same period. Cash flow from operating activities improved to INR 1,072.00 crore in March 2025, indicating a positive trend in cash generation. Overall, Jubilant Pharmo has demonstrated resilience with a recovery in profitability and growth in sales, despite facing challenges in previous years.

Is Jubilant Pharmo technically bullish or bearish?

As of December 3, 2025, Jubilant Pharma's technical trend has shifted to a bearish outlook, supported by mildly bearish MACD and KST indicators, alongside mixed signals from moving averages and Bollinger Bands.

As of 3 December 2025, the technical trend for Jubilant Pharmo has changed from mildly bullish to sideways. The current technical stance is bearish, with key indicators supporting this view. The MACD is mildly bearish on both the weekly and monthly time frames, and the KST also shows a mildly bearish trend. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the moving averages on the daily chart are mildly bullish, suggesting mixed signals. Overall, the weakness in the weekly indicators and the sideways trend suggest a bearish outlook with limited strength.

Should I buy, sell or hold Jubilant Pharmova Ltd?

Why is Jubilant Pharmova Ltd falling/rising?

As of 28-Dec, Jubilant Pharmova Ltd's stock price is at 1,065.00, down 2.25 (-0.21%), continuing a downward trend with a 2.01% loss over the past week. Despite being above its 200-day moving average, the stock shows bearish sentiment short-term, with declining investor participation and a year-to-date decline of 3.70% compared to the Sensex's 8.83% gain.

As of 28-Dec, Jubilant Pharmova Ltd's stock price is falling, currently at 1,065.00, reflecting a decrease of 2.25 (-0.21%). The stock has been on a downward trend, having lost 2.01% over the past week and 3.63% over the past month. This decline is notable as it has been losing for the last four consecutive days. <BR><BR>Investor participation appears to be decreasing, as evidenced by a significant drop in delivery volume, which fell by 54.6% compared to the five-day average. Additionally, while the stock is trading above its 200-day moving average, it is below the shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), indicating a potential bearish sentiment in the short term.<BR><BR>Despite these negative trends, the stock has a relatively attractive valuation with a return on capital employed (ROCE) of 9.9 and a PEG ratio of 1.2, suggesting that it may be undervalued compared to its peers. However, the overall performance year-to-date shows a decline of 3.70%, contrasting sharply with the Sensex, which has gained 8.83% in the same period. This disparity in performance may contribute to the stock's current downward movement.

Which are the latest news on Jubilant Pharmo?